Sunday Space + Two Full Days of RESI JPM

16 Dec

By Sougato Das, President and COO, LSN

Sougato-Das

RESI JPM 2026 expands the opportunity to connect by adding Sunday partnering and event space, giving attendees an early start to JPM Week. With RESI JPM running Monday–Tuesday, Sunday provides a strategic window to schedule investor meetings, host receptions, or bring teams together while momentum is already building across San Francisco.

RESI JPM is the only JPM conference where 700+ investors actively providing seed to Series B funding attend, alongside in-licensors seeking preclinical through Phase 2 assets. For preclinical and clinical-stage biotech, medtech, diagnostic, digital health, and AI companies, RESI JPM remains the most efficient way to connect with aligned investors and strategic partners during JPM Week. Many companies schedule 10–20 meetings in a single day, making partnering the core of the RESI experience.

New Sunday Partnering Opportunities Added

Life Science Nation is announcing additional partnering slots on Sunday, January 11, hosted at the Marriott Marquis. These meetings take place ahead of the main conference and allow attendees to secure valuable investor conversations before calendars fill up.

The Sunday Partnering Slot sign-up form is available to RESI attendees, allowing registered participants to request meetings and plan their schedules in advance.

Start JPM Week with Purpose

This added day gives companies a head start to:

  • Schedule investor or in-licensor meetings
  • Connect with fellow RESI attendees
  • Host private meetings or team gatherings

Located in the center of the JPM ecosystem, the Marriott Marquis offers a convenient and efficient setting to begin JPM Week with focused, high-value interactions.

With Sunday now in play, RESI JPM 2026 delivers more time, more access, and more opportunities to make meaningful connections before the week reaches full pace.

Register for RESI JPM 2026

Tags: , , , , , , , , , , , , , , , , , , ,

Hot Investor Mandate: Europe-Based VC Firm With Strong Track Record Invests Up to €20M, Open to All Life Science & Healthcare Sectors 

16 Dec

The firm is a leading European venture capital firm investing in early- and growth-stage life science companies. The firm focuses on biotechnology, therapeutics, medical technology, diagnostics, digital health, and life science tools. The firm has a long track record of supporting innovative companies as they translate scientific breakthroughs into high-growth businesses. To date, the firm has invested in more than 60 life science companies, including multiple successful acquisitions by large pharmaceutical and medical technology companies. Initial investment sizes typically range from EUR 5–10 million, with the potential to invest up to EUR 20 million over the life of an investment. 

The firm invests primarily in Europe and selectively in the United States across five broad areas: therapeutics, medtech, diagnostics, digital health, and biotechnology and R&D tools. Within therapeutics, the firm focuses on early-stage companies with preclinical proof-of-concept data or programs approaching clinical entry, with a preference for highly innovative technology platforms and opportunities supported by early clinical data. In other sectors, the firm prefers companies with product candidates supported by strong intellectual property that are approaching regulatory approval or companies that have already launched a first product and achieved early market traction. 

From a company and management team perspective, the firm typically seeks a board seat and places strong emphasis on experienced, high-quality management teams. At the same time, the firm actively supports highly talented entrepreneurs and works closely with portfolio companies to help drive strategic, operational, and commercial execution. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

Hot Investor Mandate: Global Pharma With Investment Subsidiary Seeks Companies Developing Novel Drugs, Open to Various Modalities

16 Dec

The firm is a publicly listed pharmaceutical company with a global workforce and an international footprint that includes over 40 branches and subsidiaries worldwide. The firm’s core businesses are active pharmaceutical ingredients and generic drugs, while the firm is rapidly expanding into innovative drug development, including small molecules, biologics, and cell and gene therapies. A U.S.-based subsidiary operates as an integrated platform with research and development, manufacturing, and commercial capabilities, supplying generic drugs to major pharmacy chains, mass retailers, and grocery channels. 

Another subsidiary of the firm is responsible for equity investments and business development activities, including in-licensing and supplier or distributor partnerships, across both the China and U.S. markets. 

The firm is most interested in companies developing novel drugs across biologics, cell therapy, gene therapy, repurposed drugs, and biosimilars. From a development-stage perspective, the firm prefers programs at or before the NDA stage, including preclinical, Phase I, Phase II, Phase III, and NDA-ready assets. 

In addition to general equity investment and business development opportunities, the firm has particular interest in late-stage clinical assets that can be in-licensed and introduced into the China market, technologies that improve API manufacturing and production efficiency, and injectable drug products. The firm is also interested in distribution rights in China for both innovative and generic drugs, as well as distribution rights in the United States, primarily for generic drugs. 

From a company and management team perspective, the firm generally favors partners with strong scientific and technical capabilities, clear development and regulatory strategies, and high-quality data packages that support clinical and commercial potential. The firm typically values management teams that demonstrate execution capability, openness to strategic collaboration, and a willingness to engage in cross-border partnerships aligned with manufacturing, regulatory, and commercialization objectives. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , , ,

Hot Investor Mandate: VC Firm With US and Asia Offices Invests in Early-Stage Life Science Companies in Seed to Series A Rounds

16 Dec

A venture capital firm with offices in US and Asia primarily invests in Seed and Series A rounds, although the firm is not stage-focused or valuation sensitive, as the core focus is on return opportunities. The firm has a global investment team covering healthcare, consumer, enterprise, frontier, fintech, and more. The firm invests globally and typically acts as a co-investor, making approximately 2–5 new portfolio investments per quarter and 2–5 follow-on investments per quarter. Initial check sizes can be up to $1M USD. 

As a generalist investor within healthcare, the firm seeks transformative technologies that shape the future of the sector. 

The firm values founders with a clear vision to solve fundamental problems at the root cause level, emphasizing cost-effective solutions that can benefit large populations. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

Hot Investor Mandate: Family Office Firm Actively Seeking Early-Stage Life Science Technologies, With a Focus on Therapeutics and Drug Development 

16 Dec

A family office based in the United States invests across a wide range of sectors, including life science and healthcare. The firm primarily focuses on early-stage opportunities from Seed to Series A and may consider Series B investments on a case-by-case basis. Typical check sizes range from $100K to several million dollars, with the ability to invest additional capital by leveraging extended family resources. The firm prefers to co-invest in life science and healthcare transactions and may consider observer seats on a case-by-case basis. While the firm has a primary focus on the U.S. market, the firm does not have geographic restrictions and is open to global opportunities. 

Within life sciences and healthcare, the firm is open to evaluating a broad range of sectors and subsectors but has a primary focus on therapeutics assets and drug development. Areas of particular interest include cell and gene therapy programs targeting autoimmune diseases and oncology indications. 

The firm does not impose specific requirements on companies or management teams. The firm expects strong underlying science and compelling data supporting the targeted disease areas. The firm values founders who communicate effectively and consistently consider investor alignment and engagement. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

How RESI Helps Investors Source Breakthrough Technologies: An Interview with Toru Jay Seo of Newsight Tech Angels 

9 Dec

By Joey Wong, Director of Investor Research, Hong Kong BD, LSN

Joey-New-Headshot

In this interview, Toru Jay Seo, Founder of Newsight Tech Angels, shares how the RESI conference series has become a reliable source for discovering high-potential early-stage life science startups. 

Toru highlights that RESI’s structured partnering, global pipeline, and clear alignment by sector and stage have directly contributed to several of his firm’s investments. 

He also reflects on the qualities he looks for in scientific founders, the value of clear communication during early investor conversations, and how entrepreneurs can best prepare to stand out in settings like RESI. 

Tags: , , , , ,

Innovator’s Pitch Challenge Winners Announced at RESI London 2025 

9 Dec

Attendees voted with their RESI Cash alongside judges’ scores to determine this year’s winners.

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

Life Science Nation is pleased to announce the winners of the Innovator’s Pitch Challenge (IPC) at RESI London 2025. This year’s competition featured 26 participating companies, each showcasing early-stage technologies to a panel of experienced investors and an audience of global attendees. 

The IPC remains a cornerstone of every RESI conference, allowing founders to present to a coordinated group of investors who provide interactive questions and valuable feedback. Attendees cast votes using their RESI Cash, which was combined with judges’ assessments to select this year’s top companies. 

Congratulations to the RESI London 2025 IPC winners: 

These companies stood out among a highly competitive group of innovators spanning therapeutics, medical devices, diagnostics, and digital health. 

Congratulations, as well, to the companies from each session who received the highest judges scores:  

Looking ahead: Applications are now open for Life Science Nation’s next European conference, taking place in Portugal on March 23, 2026. Companies interested in pitching can apply here. 

Apply to Pitch at RESI Europe

Tags: , , , , , , , , , , , ,

← Older Entries
Newer Entries →